Treg-depleting immunotherapy

Treg消耗免疫疗法

基本信息

  • 批准号:
    10370465
  • 负责人:
  • 金额:
    $ 118.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-07 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Abstract Sonoval is expanding its successful biologic drug platform technology to develop second generation versions of the cancer therapeutic Ontak, with the potential to advance the field of regulatory T cells (Tregs)-depleting immunotherapy through a mechanism previously unique to Ontak alone. Sonova;’s therapeutics will target Tregs for treatment of major solid tumors, which afflict >50,000 Americans per year, by transiently and potently depleting these CD25+ cells while being non-toxic to other cell types. Tregs contribute to cancer progression by suppressing anti-tumor immune responses Thus far, one of the lead second generation candidates has demonstrated 3-5-fold anti-tumor effect as monotherapy compared to no treatment, and in novel application, enhances check-point inhibitor (CPI) activity by up to 5-fold in murine models of solid tumors. For over a decade, Ontak was approved for treatment of cutaneous T-cell lymphoma, making it the first antibody fusion protein of non-monoclonal origin approved for use by the FDA. Ontak was also found to be effective in the treatment of several solid tumors by transient Treg depletion in the tumor microenvironment. Despite its clinical success Ontak suffered from two critical drawbacks: a 25% rate of vascular leak syndrome (VLS), and significant manufacturing inconsistencies that included variable levels of protein aggregates (up to 40%) and detergent contamination. These issues led to the drug being taken off the market in 2011. Sonoval’s second generation versions of Ontak, SON-211 and SON-301, both show reduced VLS and are potential lead drugs for development. Further, Sonoval holds IP on a novel production method that solves prior manufacturing problems and enables product to be made with 0% aggregation and no detergent. In preliminary experiments, compared to Ontak, SON-211 shows an improved safety profile; a lower dose response; and equipotent anti-tumor efficacy in 3 murine tumor models (melanoma, colon carcinoma, renal cell cancer). in these same models, SON-211 monotherapy is significantly potentiated by the addition of CPI, paving the path to novel sequential combination treatment regimens. Further, SON-211 has been show to deplete CD39+ activated Treg in the tumor microenvironment by 72%, and to increase levels of effector T cells in tumors, while not depleting resting Tregs in spleen. The purpose of this Fast Track project is to finalize lead compound identification (Phase I), and to meet safety, efficacy and manufacturing milestones (Phase II) needed to progress to IND approval. Phase I’s single Aim will be to evaluate SON-211 and SON-301 based on their levels of superiority to Ontak in safety (VLS testing), anti-tumor efficacy with and without CPI, and production efficiency of fermentation, at 5-liter scale. Phase II Aims include: 1) Determine optimal dosing regimen as anti-cancer monotherapy and as dual sequential immunotherapy with CPI; 2) Optimize production/purification; 3) Conduct pre-IND, pharmacokinetics studies of lead drug in rats; 4) Tumor repetitive dosing studies to evaluate tumor eradication and/or time to relapse in Murine tumor models.
摘要 Sonoval正在扩展其成功的生物药物平台技术,以开发第二代版本的 癌症治疗药物Ontak,有可能推进调节性T细胞(Tregs)耗尽领域 通过一种以前只有Ontak独有的机制进行免疫治疗。索诺瓦:S疗法将瞄准特雷格 用于治疗主要实体肿瘤,每年折磨着50,000美国人,通过短暂和有效的 消耗这些CD25+细胞,同时对其他类型的细胞无毒。Tregs通过以下途径促进癌症进展 到目前为止,抑制抗肿瘤免疫反应的第二代主要候选人之一已经 与不治疗相比,单一治疗显示出3-5倍的抗肿瘤效果,并且在新的应用中, 在实体瘤小鼠模型中,将检查点抑制物(CPI)活性提高高达5倍。 十多年来,Ontak被批准用于治疗皮肤T细胞淋巴瘤,使其成为第一个抗体 经FDA批准使用的非克隆来源的融合蛋白。Ontak也被发现对治疗 肿瘤微环境下一过性Treg去除治疗几种实体瘤尽管它的 临床成功Ontak有两个关键缺陷:血管渗漏综合征(VLS)的发生率为25%; 重大制造不一致,包括不同水平的蛋白质聚集体(高达40%)和 洗涤剂污染。这些问题导致该药于2011年下架。 Sonoval的第二代Ontak版本SON-211和SON-301都显示出更低的VLS,并且 潜在的用于开发的先导药物。此外,Sonoval拥有一种解决先前问题的新生产方法的知识产权 制造问题,并使产品能够生产出0%的团聚和不含洗涤剂的产品。在预赛中 实验表明,与Ontak相比,SON-211具有更好的安全性;剂量反应更低;以及 在3种小鼠肿瘤模型(黑色素瘤、结肠癌、肾癌)中具有相同的抗肿瘤效果。穿着这些 同样的型号,SON-211单一疗法通过添加CPI显著增强,为创新铺平了道路 序贯联合治疗方案。此外,SON-211已被证明耗尽CD39+激活Treg 在肿瘤微环境中增加72%,并增加肿瘤中效应T细胞的水平,同时不耗尽 在脾里休息的树。此快速通道项目的目的是最终确定铅化合物识别(阶段 I),并达到IND批准所需的安全性、有效性和制造里程碑(第二阶段)。 第一阶段的单一目标将是评估SON-211和SON-301在#年相对于Ontak的优势水平 安全性(VLS测试)、使用和不使用CPI的抗肿瘤效果,以及发酵的生产效率,在5升 比例。第二阶段的目标包括:1)确定抗癌单药和双药的最佳给药方案 使用CPI进行序贯免疫治疗;2)优化生产/纯化;3)进行前IND,药代动力学 铅药物在大鼠身上的研究;4)肿瘤重复给药研究,以评估肿瘤根除和/或时间 小鼠肿瘤模型的复发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM Ramses BISHAI其他文献

WILLIAM Ramses BISHAI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM Ramses BISHAI', 18)}}的其他基金

Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV
介导结核病和结核病艾滋病毒性别差异的遗传和激素机制
  • 批准号:
    10557906
  • 财政年份:
    2022
  • 资助金额:
    $ 118.86万
  • 项目类别:
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV
介导结核病和结核病艾滋病毒性别差异的遗传和激素机制
  • 批准号:
    10484064
  • 财政年份:
    2022
  • 资助金额:
    $ 118.86万
  • 项目类别:
Microbiology, Immunology, Animal Modeling and Imaging
微生物学、免疫学、动物建模和成像
  • 批准号:
    10431023
  • 财政年份:
    2022
  • 资助金额:
    $ 118.86万
  • 项目类别:
Microbiology, Immunology, Animal Modeling and Imaging
微生物学、免疫学、动物建模和成像
  • 批准号:
    10593152
  • 财政年份:
    2022
  • 资助金额:
    $ 118.86万
  • 项目类别:
A STINGing vaccine for TB
结核病疫苗
  • 批准号:
    10415895
  • 财政年份:
    2020
  • 资助金额:
    $ 118.86万
  • 项目类别:
Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
  • 批准号:
    10556322
  • 财政年份:
    2020
  • 资助金额:
    $ 118.86万
  • 项目类别:
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
结核病和结核病艾滋病毒的谷氨酰胺代谢抑制剂:作为具有抗菌活性的宿主导向疗法的双重作用
  • 批准号:
    10686328
  • 财政年份:
    2020
  • 资助金额:
    $ 118.86万
  • 项目类别:
Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
  • 批准号:
    10012368
  • 财政年份:
    2020
  • 资助金额:
    $ 118.86万
  • 项目类别:
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
结核病和结核病艾滋病毒的谷氨酰胺代谢抑制剂:具有抗菌活性的宿主导向疗法的双重作用
  • 批准号:
    10456845
  • 财政年份:
    2020
  • 资助金额:
    $ 118.86万
  • 项目类别:
Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
  • 批准号:
    10320031
  • 财政年份:
    2020
  • 资助金额:
    $ 118.86万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 118.86万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了